Holen Sie sich die Stockscreener-App
31.87
3.25%
-1.07
Handel nachbörslich:
31.52
-0.35
-1.10%
Schlusskurs vom Vortag:
$32.94
Offen:
$31.92
24-Stunden-Volumen:
3.29M
Relative Volume:
1.17
Marktkapitalisierung:
$4.05B
Einnahmen:
$638.78M
Nettoeinkommen (Verlust:
$-22.66M
KGV:
-182.74
EPS:
-0.1744
Netto-Cashflow:
$122.18M
1W Leistung:
+0.38%
1M Leistung:
+34.59%
6M Leistung:
+93.15%
1J Leistung:
+195.37%
1-Tages-Spanne:
$31.30
$33.36
1-Wochen-Bereich:
$31.27
$36.59
52-Wochen-Spanne:
$10.63
$36.59
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY, HNGE
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
31.87 | 4.41B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
159.71 | 24.90B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
66.84 | 13.00B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
48.61 | 9.13B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
84.92 | 7.12B | 1.34B | 230.70M | 440.96M | 2.6695 |
HNGE
Hinge Health Inc
|
70.38 | 5.37B | 646.34M | -512.40M | 202.76M | -6.6871 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-31 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-12-02 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | Eingeleitet | Piper Sandler | Neutral |
| 2025-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | Eingeleitet | Leerink Partners | Outperform |
| 2024-07-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-07-18 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-10 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-05-01 | Herabstufung | TD Cowen | Buy → Hold |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10X Genomics stock hits 52-week high at 36.0 USD - Investing.com
10x Genomics (TXG): Buy, Sell, or Hold Post Q1 Earnings? - Yahoo Finance
10x Genomics boosts single cell proteomics with acquisition of Proteintech Genomics - Select Science
Insider Sell: Shehnaaz Suliman Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) director Suliman sells 5,723 shares in Rule 10b5-1 trades - Stock Titan
TXG - Finviz
10X Genomics stock rises on Cleveland Clinic partnership - Investing.com
10x Genomics (TXG) Partners with Cleveland Clinic for Bladder Ca - GuruFocus
10X Genomics (TXG) Stock Surges 4% Following Cleveland Clinic Bladder Cancer Research Agreement - Blockonomi
10X Genomics Inc (TXG) Institutional Confidence - TradingKey
10X Genomics stock rises on Cleveland Clinic partnership By Investing.com - Investing.com India
10x Genomics partners with Cleveland Clinic on bladder cancer study - Investing.com
10X Genomics Inc (TXG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
10X Genomics Inc (TXG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
10X Genomics Inc (TXG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
10X Genomics Inc (TXG) Valuation: PE, PB & Fair Value Analysis - TradingKey
10X Genomics Inc (TXG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
10x Genomics, Cleveland Clinic study aims to predict bladder cancer treatment response - Stock Titan
10X Genomics Inc (TXG) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
10X Genomics Inc (TXG) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
10X Genomics Inc (TXG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
TXG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TXG (Nasdaq) RSU vesting entries listed on Form 144 with JP Morgan intermediary - Stock Titan
Human Cell Atlas leader’s tie to 10x Genomics raises conflict-of-interest questions - statnews.com
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics buys Proteintech Genomics - MSN
TXG Gains From Proteintech Deal, Expands Multiomics Capabilities - TradingView
10x Genomics: Temporary Pain, Long-Term Gain As Atera Rollout Approaches (NASDAQ:TXG) - Seeking Alpha
Is It Too Late To Consider 10x Genomics (TXG) After Its Recent 187% Surge? - Yahoo Finance
10x Genomics (TXG) Expands Capabilities with Proteintech Genomics Acquisition - GuruFocus
10x Genomics Acquires Proteintech Genomics to Expand Single-Cell Proteomics Portfolio - citybiz
Is 10x Genomics' Latest Acquisition a Game-Changer for Proteomics - Kavout
10x Genomics acquires Proteintech Genomics division By Investing.com - Investing.com South Africa
10x Genomics acquires Proteintech Genomics division - Investing.com
10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Group - Morningstar
CenterBook Partners LP Invests $3.76 Million in 10x Genomics $TXG - MarketBeat
10x Genomics (TXG) awards 8,829 RSUs to company director - Stock Titan
10x Genomics (NASDAQ: TXG) grants 8,829 RSUs to director Suliman - Stock Titan
10x Genomics (TXG) awards 8,829 RSUs to board director - Stock Titan
10x Genomics (TXG) awards director Kimberly Popovits 8,829 RSUs - Stock Titan
10x Genomics (TXG) director receives 8,829 RSUs vesting from 2026 - Stock Titan
10x Genomics (TXG) director receives 8,829 RSU grant, lifts holdings - Stock Titan
10x Genomics Shareholders Reelect Directors, Ratify Auditor - TipRanks
10x Genomics, Inc. acquired Proteintech Genomics from ProteinTech Group Inc. - marketscreener.com
10x Genomics shareholders elect directors and approve proposals at annual meeting - Investing.com
10x Genomics (NASDAQ: TXG) investors approve full 2026 meeting agenda - Stock Titan
TXG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Deutsche Bank Adjusts Price Target on 10x Genomics to $30 From $23, Maintains Hold Rating - marketscreener.com
10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors. - The Motley Fool
10x Genomics (TXG) Rises Modestly as Support Holds Despite Lingering UncertaintyKAMA Signal - newsline.com
10X Genomics Hits Day High with 9.72% Surge, Outperforming Market - Markets Mojo
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):